Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Toshifumi TadaTakashi KumadaAtsushi HiraokaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiHiroki NishikawaKunihiko TsujiToru IshikawaKazuto TajiriYuichi KoshiyamaHidenori ToyodaChikara OgawaTakeshi HatanakaSatoru KakizakiKazuhito KawataHideko OhamaFujimasa TadaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiTakashi NishimuraMichitaka ImaiHisashi KosakaAtsushi NaganumaTomomitsu MatonoTomoko AokiHidekatsu KurodaYutaka YataYohei KoizumiShinichiro NakamuraHirayuki EnomotoMasaki KaiboriYoichi HiasaMasatoshi Kudonull nullnull nullPublished in: Alimentary pharmacology & therapeutics (2024)
Patients who are treated with Atezo/Bev and meet the inclusion criteria for the phase 3 IMbrave150 trial, as well as those who do not meet the inclusion criteria but have good liver function, have a good prognosis for survival.